查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999266

医药低温运输市场：2026-2032年全球市场预测（依产品类型、包装类型、温度范围、设备、服务类型、应用程式和最终用户划分）

Cold-chain Pharma Market by Product Type, Packaging Type, Temperature Range, Equipment, Service Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，医药低温运输市场价值将达到 167.8 亿美元，到 2026 年将成长至 182.8 亿美元，到 2032 年将达到 314.7 亿美元，复合年增长率为 9.39%。

主要市场统计数据
基准年 2025 167.8亿美元
预计年份：2026年 182.8亿美元
预测年份：2032年 314.7亿美元
复合年增长率 (%) 9.39%

本文简要介绍了低温运输物流在快速发展的全球医疗保健生态系统中对药品运输的复杂性和战略重要性。

药品低温运输生态係是科学、物流和法律规范复杂交织的产物，构成了现代治疗药物传递的基础。随着生物製药、细胞和基因疗法以及新一代疫苗的不断进步，维持产品在时间和空间上的完整性所需的技术要求也日益提高，同时，需要协作以确保符合温度规范的利益相关人员数量也在不断增加。

变革性的变化正在重塑药品低温运输的格局，而技术和监管的转变以及以患者为中心的配送模式正在影响营运。

随着技术、法规和客户期望的融合，产业趋势正在迅速变化，重新定义高效低温运输营运的组成要素。数位化和遥测技术已从实验性试点阶段发展成为不可或缺的控制工具。持续温度监测、预测分析和基于区块链的可追溯性正日益融入整个储存和运输流程，从而能够快速回应突发事件并提高监管透明度。

本研究评估了美国近期关税措施和到 2025 年的贸易政策转变如何增加供应链的成本压力并改变运输路线决策。

近期源自美国的关税措施以及2025年前的贸易政策变化，为医药低温运输网路带来了新的成本和运输路线的考量。关税措施正在改变采购和跨境运输的经济格局，影响企业在生产、仓储和加工环节选址方面的决策。在实践中，企业正透过供应商多元化、调整入境运输路线以及更多地依赖区域网路来应对这些变化，以降低关税波动带来的风险，并维持对时间要求严格的冷链运输。

明确详细的细分，揭示产品类型、包装、温度控制、设备、服务、应用和最终用户如何决定营运设计。

详细的细分观点能够明确运作复杂性集中在何处，以及哪些能力能够最大程度地降低风险。产品类型的差异至关重要。生物製药需要针对单株抗体、血浆衍生疗法和重组蛋白制定相应的通讯协定，这与凝血因子和免疫球蛋白等血液和血浆製品的处理和储存要求有所不同。细胞和基因疗法也有其自身的限制；同种异体和自体细胞疗法以及基因疗法通常需要低温炼和专用设备来处理临床试验材料，包括试剂盒和临床实验药物。胰岛素和肽激素的设计需要考虑与GLP-1和胰岛素变异相关的因素。特殊药品，包括生育治疗药物和特殊注射剂，需要独特的处理方法和给药方案。疫苗包括大流行和新兴感染疾病疫苗、常规免疫疫苗、旅行疫苗和特殊疫苗，其中大流行疫苗还包括mRNA和病毒载体等亚类，这些亚类需要独特的低温处理要求。

美洲、欧洲、中东、非洲和亚太地区在趋势和基础设施方面存在区域差异，因此需要采取差异化的低温运输策略。

基础设施、管理体制和商业惯例方面的区域差异意味着美洲、欧洲、中东、非洲和亚太地区的营运环境差异显着，因此需要针对每个地区制定量身定制的策略。在美洲，成熟的温控仓储、强大的航空货运网络和不断扩展的末端物流生态系统为快速商业化提供了支援。然而，广大的地域和细微的区域监管差异通常需要区域枢纽和合格的末端物流合作伙伴来确保全国覆盖。

构成医药低温运输生态系的公司之间的竞争与合作行为，包括竞争、专业化和服务差异化。

在医药低温运输领域，企业行为展现出专业化、伙伴关係和垂直整合结合的趋势，旨在追求竞争优势。一些供应商专注于高科技细分市场，例如低温物流、超低温储存和以临床试验为中心的服务，透过投资专有处理通讯协定、专用设施和严格的认证项目，在产品安全性和可靠性方面脱颖而出。而其他参与企业则更注重业务广度，透过提供整合储存、运输、合规服务和数位化视觉化的端到端解决方案，简化製造商和医疗保健机构的供应商管理。

为高阶主管提供切实可行的建议，以确保低温运输营运的未来发展，包括投资、伙伴关係、合规和人才策略。

领导者必须采取多管齐下的策略，以确保低温运输营运的未来发展，并在日益严峻的环境中创造价值。首先，应优先投资于可视性和分析技术，提供贯穿整个运输和预存流程的即时遥测数据，从而实现主动异常管理和更完善的审计追踪。除了技术投资外，还应实施流程控制、完善的合格通讯协定和定期审计，以确保资料有经过检验的程序支援。

高度透明的调查方法，详细说明了资料来源、检验程序、相关人员访谈以及应用于低温运输评估的分析框架。

本调查方法结合了一手和二级资讯来源，为分析奠定了严谨透明的基础。一手资料包括对製造商、物流供应商和临床检测实验室的供应链、品质和监管负责人进行的结构化访谈，以及现场考察和流程验证，以检验设备、包装和温度控制措施。这些访谈重点在于运输路线检验、最后一公里配送异常情况以及设备合格的经验，旨在了解实际应用中的限制和应对策略。

总结了药品低温运输运输的弹性和合规性策略意义、剩余风险和实际途径。

总之，医药低温运输正处于转捩点，产品创新、监管趋严以及地缘政治趋势都促使人们对卓越营运提出了更高的要求。积极调整在遥测技术、验证包装和区域网路柔软性投资的机构，更有可能降低风险并加快关键治疗方法的取得。同时，在贸易政策波动和产品系列日益复杂的背景下，动态采购、完善的合格流程以及更强有力的合约保障措施对于维持供应链的连续性至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 医药低温运输市场：依产品类型划分

  • 生技药品
    • 单株抗体
    • 血浆衍生疗法
    • 重组蛋白质和酶
  • 血液和血浆製品
    • 凝血因子
    • 免疫球蛋白
  • 细胞和基因治疗
    • 异体细胞疗法
    • 自体细胞疗法
    • 基因治疗
  • 临床试验用材料
    • 配件/套件
    • 临床实验药物
  • 胰岛素激素
    • GLP-1 和其他胜肽激素
    • 胰岛素
  • 特种药品
    • 不孕不育及生殖医学
    • 特製注射药物
  • 疫苗
    • 大流行病和新兴感染疾病疫苗
      • 药效疫苗
      • 病毒载体疫苗
    • 常规免疫疫苗
    • 旅行疫苗和特殊疫苗

第九章 医药低温运输市场：依包装类型划分

  • 活性包装
  • 被动式包装

第十章：医药低温运输市场：依温度范围划分

  • 低温（低于-150 度C）
    • 低温包装
    • 干货运输
    • 液态氮蒸气储存
  • 冰冻（约 20 至 -40°C）
    • 包装
    • 贮存
    • 运输
  • 冷藏（2-8 ℃）
    • 包装
    • 贮存
    • 运输
  • 超低温（-60 至 -86 度C）
    • 包装
    • 贮存
    • 运输

第十一章 医药低温运输市场：依设备划分

  • 储存装置
    • 冷藏室和仓库
    • 低温冷冻库和液态氮冷却罐
    • 冷冻库（约20 ℃）
    • 医药冷藏库（2-8 ℃）
    • 超冷冻库（-80 ℃）
  • 运输设备
    • 航空货运货柜（ULD）
    • 最后一公里用的可携式冷藏箱
    • 船用冷藏货柜
    • 冷藏卡车和厢型车

第十二章 医药低温运输市场：依服务类型划分

  • 临床实验室物流
    • 辅助管理
    • 为患者提供直接服务
    • 向工厂供应和退货
  • 合规性和品质
    • 审计和GDP培训
    • 运输路线的验证和风险评估
    • 合格评估（IQ/OQ/PQ）
  • 仓储管理
    • 低温储存
    • 长期GMP储存
  • 运输
    • 首英里接送
    • 最后一公里配送
    • 长途
    • 逆向物流和退货

第十三章 医药低温运输市场：依应用领域划分

  • 临床检测
  • 商业分销
  • 直接送达/宅配患者
  • 人道援助/非政府组织物资
  • 为专业药局提供履约
  • 疫苗宣传活动

第十四章 医药低温运输市场：依最终用户划分

  • 血库和血浆中心
  • 临床试验设施及储存场所
  • CMO 和 CDMO
  • CRO
  • 医院和诊所
  • 製药和生物技术製造商
    • 新兴生技公司
    • 大型製药公司
  • 零售药局和专科药局
  • 疫苗接种中心和公共卫生机构

第十五章：医药低温运输市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 医药低温运输市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 药品低温运输市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章：美国药品低温运输市场

第十九章：中国医药低温运输市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Americold Realty Trust, Inc.
  • AmerisourceBergen Corporation
  • BioCold Technologies SAS
  • CH Robinson Worldwide, Inc.
  • Catalent, Inc.
  • Clinigen Group PLC
  • Conestoga Cold Storage Ltd.
  • Continental AG
  • CWT Ltd.
  • DB Schenker
  • DHL International GmbH
  • DSV A/S
  • Emergent Cold LatAm Management LLC
  • FedEx Corporation
  • FreezPak Logistics
  • HCL Technologies Limited
  • Helapet ltd.
  • Interstate Cold Storage, Inc.
  • JWD InfoLogistics Public Co. Ltd.
  • Keppel Telecommunications & Transportation Ltd
  • Kerry Logistics Network Limited（SF Holding Co., Ltd.）
  • Kuehne+Nagel Management AG
  • Lineage, Inc.
  • Maersk A/S
  • NewCold Cooperatief UA
  • OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
  • SCG Logistics Management Co Ltd.
  • Tiong Nam Logistics Holdings Berhad
  • United Parcel Service, Inc.
  • Ych Group
  • Yusen Logistics Group
Product Code: MRR-7E6E70985BD9

The Cold-chain Pharma Market was valued at USD 16.78 billion in 2025 and is projected to grow to USD 18.28 billion in 2026, with a CAGR of 9.39%, reaching USD 31.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 16.78 billion
Estimated Year [2026] USD 18.28 billion
Forecast Year [2032] USD 31.47 billion
CAGR (%) 9.39%

A concise introduction to the complexity and strategic importance of cold-chain logistics for pharmaceuticals in a rapidly evolving global healthcare ecosystem

The cold-chain pharmaceutical ecosystem is a complex intersection of science, logistics and regulatory oversight that underpins modern therapeutics delivery. Advances in biologics, cell and gene therapies, and next-generation vaccines have increased the technical stringency required to preserve product integrity across time and distance, while expanding the number of stakeholders who must coordinate to maintain compliant temperature profiles.

Against this backdrop, supply chain leaders face pressures from rising demand for direct-to-patient fulfillment, heightened regulatory scrutiny, and the need to balance speed with reliability. Operational decisions now extend from packaging selection to route design and last-mile execution, each with implications for clinical outcomes and commercial viability. Moreover, the industry must integrate new equipment classes, from ultra-low freezers to cryogenic storage and purpose-built transport assets, while ensuring qualification and validation across complex multimodal flows.

This introduction frames the subsequent analysis by highlighting the interplay between product complexity, temperature control regimes, and service modalities. It sets the stage for an evidence-driven examination of transformative forces influencing capital allocation, partnership strategies, and risk management across pharmaceutical cold chains.

Transformative shifts reshaping the cold-chain pharma landscape driven by technology, regulatory change, and patient-centric distribution models impacting operations

Industry dynamics are shifting at pace as technology, regulations and customer expectations converge to redefine what constitutes an effective cold-chain operation. Digitization and telemetry have moved from experimental pilots to essential controls; continuous temperature monitoring, predictive analytics and blockchain-based traceability are increasingly embedded across storage and transport, enabling faster exception handling and improved regulatory transparency.

Concurrently, regulatory frameworks are evolving to reflect product innovation and higher patient-safety requisites. Good Distribution Practice enforcement and lane validation expectations have expanded, prompting firms to strengthen qualification protocols and invest in independent audits and training. At the same time, the rise of patient-centric distribution models such as direct-to-patient services is forcing a rethink of packaging design, last-mile solutions and temperature resiliency to preserve both efficacy and patient experience.

Operationally, climate resilience and sustainability are reshaping procurement and equipment lifecycles; companies are evaluating energy-efficient ULT freezers, low-emission transport options and circular packaging strategies. Taken together, these transformative shifts demand integrated strategies that align technical capabilities, regulatory compliance and commercial imperatives to maintain product integrity and ensure timely access to critical medicines.

Assessing how recent US tariff measures and trade policy shifts through 2025 are aggregating supply chain cost pressure and altering routing decisions

Recent tariff actions and trade policy changes originating from the United States through 2025 have introduced new cost and routing considerations for cold-chain pharmaceutical networks. Tariff measures alter the economics of sourcing and cross-border movement, influencing where firms choose to locate manufacturing, storage and finishing activities. In practice, organizations have responded by diversifying supplier bases, recalibrating inbound lane decisions and increasing reliance on regionalized networks to reduce exposure to tariff volatility and preserve time-sensitive cold flows.

These trade shifts also interact with modal selection and inventory strategies. Where tariffs elevate landed costs, companies may favor higher-capacity, less frequent shipments to dilute fixed expenses, or alternatively move to nearshoring and regional manufacturing to minimize cross-border touchpoints. Such changes have downstream implications for packaging and equipment choices, particularly when different temperature ranges require specialized containers or cryogenic handling that complicates rerouting.

Moreover, tariff-related uncertainty places a premium on contractual agility and trade compliance capabilities. Organizations that invest in robust tariff classification, free trade agreement utilization and dynamic contract terms are better positioned to mitigate sudden policy moves. In addition, scenario planning and lane-level risk assessments have become standard tools for supply chain leaders seeking to preserve product integrity while optimizing cost and service under shifting trade conditions.

Deep segmentation clarity revealing how product types, packaging, temperature control, equipment, services, applications, and end users dictate operational design

A granular segmentation lens clarifies where operational complexity is concentrated and which capabilities deliver the greatest risk mitigation. Product-type distinctions matter: biologics demand protocols for monoclonal antibodies, plasma-derived therapeutics and recombinant proteins that differ from the handling and storage needs of blood and plasma products such as coagulation factors and immunoglobulins. Cell and gene therapies present their own constraints, with allogeneic and autologous cell therapies and gene therapies often requiring cryogenic chains or specialized ancillaries used in clinical trial materials, including kits and investigational medicinal products. Insulins and peptide hormones bring design considerations for GLP-1 and insulin variants, while specialty pharmaceuticals including fertility medicines and specialty injectables impose bespoke handling and delivery timelines. Vaccines span pandemic and emerging vaccines, routine immunization and travel or specialty vaccines, with pandemic vaccines introducing mRNA and viral vector subcategories that drive unique cold requirements.

Packaging choices influence reliability and flexibility across those product groups. Active packaging solutions provide powered temperature control for highly sensitive payloads, whereas passive packaging affords simpler, proven containment for many refrigerated and frozen flows. Temperature-range segmentation demands distinct options from cryogenic solutions at or below -150 °C with cryo packaging and dry shippers, to frozen and ultra-low classes and the ubiquitous refrigerated 2-8 °C band where packaging, storage and transportation modalities must be matched to product stability profiles.

Equipment selection reinforces these distinctions. Storage equipment spans from cold rooms and GMP warehouses to cryogenic freezers, LN2 tanks, pharmaceutical refrigerators and ultra-low freezers, while transport fleets encompass air cargo containers, last-mile portable coolers, ocean reefer containers and reefer trucks. Service types overlay these hardware choices: clinical trial logistics that include ancillary management and direct-to-patient services; compliance and quality offerings such as audits, GDP training and lane validation; storage and warehousing solutions that include cryogenic and long-term GMP storage; and transportation services covering first-mile, line-haul and last-mile delivery plus reverse logistics and returns. Application contexts shape operational priorities, whether supporting clinical trials, commercial distribution, home delivery, humanitarian supply, specialty pharmacy fulfilment or vaccination campaigns.

End-user needs ultimately drive configuration. Blood banks, clinical trial sites and depots, CMOs, CDMOs and CROs require different SLA and qualification intensity compared with hospitals, clinics, retail specialty pharmacies and public health vaccination centers. Pharma and biotech manufacturers, from emerging biotech to large pharmaceutical companies, often act as the integrators of these requirements, defining service levels, validation expectations and capital investment criteria. Understanding how each segment interacts with packaging, temperature regimes, equipment and service models is essential to designing resilient cold-chain solutions that are fit for purpose and scalable across therapeutic categories.

Regional dynamics and infrastructure contrasts across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive differentiated cold-chain strategies

Regional infrastructure, regulatory regimes and commercial practices create materially different operating environments across the Americas, Europe Middle East & Africa, and Asia-Pacific, requiring tailored strategies for each geography. In the Americas, maturity in temperature-controlled warehousing, a strong air cargo network and a growing last-mile ecosystem support rapid commercialization, but vast distances and localized regulatory nuances mean that regional hubs and qualified last-mile partners are often prerequisites for nationwide coverage.

In Europe, Middle East & Africa, dense cross-border trade within the European Union coexists with highly variable capabilities across other markets, necessitating robust lane validation and comprehensive compliance programs to harmonize operations. The regulatory emphasis on GDP and lane qualification in many EMEA jurisdictions places a premium on audit-ready documentation and validated cold-chain partners, while infrastructure gaps in parts of the region can drive investment in contingency planning and purpose-built storage nodes.

Asia-Pacific delivers a heterogeneous mix of advanced hubs and emerging markets. Rapid vaccine rollouts and biotechnology innovation have accelerated investments in ultra-low and cryogenic storage in major markets, whereas emerging economies often require creative last-mile and packaging adaptations to contend with climatic variation and limited cold-room capacity. Across all regions, cross-border trade dynamics and trade policy changes influence network design, so a regionalized approach that blends centralized centers of excellence with local operational capacity reduces risk and improves responsiveness to demand shocks.

Competitive and collaborative company behaviors shaping the cold-chain pharmaceutical ecosystem including partnerships, specialization, and service differentiation

Company behaviors in the cold-chain pharmaceutical space reveal a mix of specialization, partnership and vertical integration as firms pursue competitive advantage. Some providers focus on deep technical niches-such as cryogenic logistics, ultra-low temperature storage or clinical-trial-centric services-investing in proprietary handling protocols, specialized equipment fleets and rigorous qualification programs to differentiate on product safety and reliability. Other players emphasize breadth, offering end-to-end solutions that combine storage, transport, compliance services and digital visibility, thereby simplifying supplier management for manufacturers and healthcare providers.

Strategic partnerships and alliances are increasingly common, enabling companies to marry local last-mile expertise with global air cargo and warehousing capabilities. Collaboration with technology vendors provides telemetry, predictive maintenance and analytic tooling that translate operational data into fewer temperature excursions and faster root-cause analysis. Meanwhile, a number of organizations pursue selective vertical integration-bringing storage or packaging capabilities in-house-to safeguard control over critical flows during product launches or pandemic-scale campaigns.

From the buyer perspective, selection criteria are shifting beyond price to emphasize demonstrable GDP compliance, lane validation experience, failure-mode analysis, and the ability to scale rapidly during demand surges. Companies that invest in cross-functional teams combining regulatory, quality and operations expertise are better positioned to win long-term engagements with manufacturers and health systems.

Actionable recommendations for senior executives to future-proof cold-chain operations through investment, partnerships, compliance, and workforce strategy

Leaders must adopt a multi-dimensional strategy to future-proof cold-chain operations and capture value in an increasingly demanding environment. First, prioritize investments in visibility and analytics that provide real-time telemetry across transport and storage, enabling proactive exception management and stronger audit trails. Complement technology investments with process controls, robust qualification protocols and recurring audits to ensure data is supported by validated procedures.

Second, pursue a regionalized network design that balances centralized centers of excellence for high-complexity products with localized last-mile capabilities to guarantee service continuity. Where trade policy or tariffs create volatility, nearshoring and diversified supplier strategies reduce exposure and shorten lead times. Third, update packaging and equipment policies to reflect evolving product mixes; specify active or passive packaging solutions aligned to temperature ranges from cryogenic to refrigerated 2-8 °C, and standardize equipment qualification across warehouses and transport assets to reduce variability.

Fourth, strengthen commercial contracts and procurement practices to include flexible terms for surge capacity, clear responsibilities for exception handling and shared obligations for qualification. Fifth, invest in workforce capability through targeted GDP training and cross-functional simulations that include quality, operations and regulatory teams, ensuring readiness for complex launches and emergency responses. Finally, embed sustainability objectives into CAPEX and lifecycle decisions, selecting energy-efficient equipment and circular packaging models where they also reinforce reliability and compliance.

Transparent research methodology detailing data sources, validation steps, stakeholder interviews, and analytical frameworks applied to cold-chain assessment

The research methodology combined primary and secondary evidence streams to create a rigorous, transparent foundation for analysis. Primary inputs included structured interviews with supply chain, quality and regulatory leaders across manufacturers, logistics providers and clinical trial organizations, supported by operational site visits and process walkthroughs that validated equipment, packaging and temperature-control practices. These interviews emphasized lane validation experiences, last-mile exceptions, and equipment qualification practices to capture real-world constraints and mitigation approaches.

Secondary sources comprised regulatory guidelines, technical standards, trade policy documents and equipment specifications that were synthesized to ensure alignment with current compliance expectations. A multi-step validation process reconciled interview findings with documentary evidence, and key assertions were cross-checked against multiple independent sources where available. Analytical frameworks incorporated failure-mode effects analysis for high-risk lanes, scenario-based planning for tariff and trade disruptions, and capability-matrix mapping to link product types to packaging and equipment requirements.

Throughout the process, care was taken to anonymize sensitive operational details and to prioritize reproducibility: assumptions and inclusion criteria are documented, and methodological limitations are acknowledged, including variability across jurisdictions and the rapid evolution of technology and regulatory practice.

Concluding synthesis of strategic implications, lingering risks, and pragmatic pathways for resilient and compliant cold-chain pharma delivery

In closing, the cold-chain pharmaceutical landscape is at an inflection point where product innovation, regulatory rigor and geopolitical dynamics collectively raise the bar for operational excellence. Organizations that proactively align investments in telemetry, validated packaging, and regional network flexibility will reduce risk and accelerate access to critical therapies. At the same time, trade policy volatility and increasing complexity in product portfolios require dynamic procurement, robust qualification practices and stronger contractual protections to maintain continuity.

Lingering risks include infrastructure variability across regions, talent shortages for specialized handling, and the potential for tariff or trade disruptions to disrupt established lanes. However, pragmatic pathways exist: prioritize auditable processes, cultivate partnerships that combine global reach with local execution, and invest in workforce and technology capabilities that translate data into decisive action. Executives who integrate these dimensions into a coherent strategic roadmap will not only protect product integrity but also create operational agility that supports rapid launches and resilient commercial supply.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cold-chain Pharma Market, by Product Type

  • 8.1. Biologics
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Plasma-Derived Therapeutics
    • 8.1.3. Recombinant Proteins & Enzymes
  • 8.2. Blood & Plasma Products
    • 8.2.1. Coagulation Factors
    • 8.2.2. Immunoglobulins
  • 8.3. Cell & Gene Therapies
    • 8.3.1. Allogeneic Cell Therapies
    • 8.3.2. Autologous Cell Therapies
    • 8.3.3. Gene Therapies
  • 8.4. Clinical Trial Materials
    • 8.4.1. Ancillaries & Kits
    • 8.4.2. Investigational Medicinal Products
  • 8.5. Insulins & Hormones
    • 8.5.1. GLP-1 & Other Peptide Hormones
    • 8.5.2. Insulin
  • 8.6. Specialty Pharmaceuticals
    • 8.6.1. Fertility & Reproductive Medicines
    • 8.6.2. Specialty Injectables
  • 8.7. Vaccines
    • 8.7.1. Pandemic & Emerging Vaccines
      • 8.7.1.1. mRNA Vaccines
      • 8.7.1.2. Viral Vector Vaccines
    • 8.7.2. Routine Immunization Vaccines
    • 8.7.3. Travel & Specialty Vaccines

9. Cold-chain Pharma Market, by Packaging Type

  • 9.1. Active Packaging
  • 9.2. Passive Packaging

10. Cold-chain Pharma Market, by Temperature Range

  • 10.1. Cryogenic (<= -150 °C)
    • 10.1.1. Cryo Packaging
    • 10.1.2. Dry Shipper Transport
    • 10.1.3. LN2 Vapor Storage
  • 10.2. Frozen (-20 To -40 °C)
    • 10.2.1. Packaging
    • 10.2.2. Storage
    • 10.2.3. Transportation
  • 10.3. Refrigerated (2-8 °C)
    • 10.3.1. Packaging
    • 10.3.2. Storage
    • 10.3.3. Transportation
  • 10.4. Ultra-Low (-60 To -86 °C)
    • 10.4.1. Packaging
    • 10.4.2. Storage
    • 10.4.3. Transportation

11. Cold-chain Pharma Market, by Equipment

  • 11.1. Storage Equipment
    • 11.1.1. Cold Rooms & Warehouses
    • 11.1.2. Cryogenic Freezers & LN2 Tanks
    • 11.1.3. Freezers (-20 °C Class)
    • 11.1.4. Pharmaceutical Refrigerators (2-8 °C)
    • 11.1.5. ULT Freezers (-80 °C Class)
  • 11.2. Transport Equipment
    • 11.2.1. Air Cargo Containers (ULDs)
    • 11.2.2. Last-Mile Portable Coolers
    • 11.2.3. Ocean Reefer Containers
    • 11.2.4. Reefer Trucks & Vans

12. Cold-chain Pharma Market, by Service Type

  • 12.1. Clinical Trial Logistics
    • 12.1.1. Ancillary Management
    • 12.1.2. Direct-To-Patient Services
    • 12.1.3. Site Supply And Returns
  • 12.2. Compliance & Quality
    • 12.2.1. Audits & GDP Training
    • 12.2.2. Lane Validation & Risk Assessment
    • 12.2.3. Qualification (IQ/OQ/PQ)
  • 12.3. Storage & Warehousing
    • 12.3.1. Cryogenic Storage
    • 12.3.2. Long-Term GMP Storage
  • 12.4. Transportation
    • 12.4.1. First-Mile Pickup
    • 12.4.2. Last-Mile Delivery
    • 12.4.3. Line-Haul Transport
    • 12.4.4. Reverse Logistics & Returns

13. Cold-chain Pharma Market, by Application

  • 13.1. Clinical Trials
  • 13.2. Commercial Distribution
  • 13.3. Direct-To-Patient/Home Delivery
  • 13.4. Humanitarian & NGO Supply
  • 13.5. Specialty Pharmacy Fulfillment
  • 13.6. Vaccination Campaigns

14. Cold-chain Pharma Market, by End User

  • 14.1. Blood Banks & Plasma Centers
  • 14.2. Clinical Trial Sites & Depots
  • 14.3. CMOs & CDMOs
  • 14.4. CROs
  • 14.5. Hospitals & Clinics
  • 14.6. Pharma & Biotech Manufacturers
    • 14.6.1. Emerging Biotech
    • 14.6.2. Large Pharmaceutical Companies
  • 14.7. Retail & Specialty Pharmacies
  • 14.8. Vaccination Centers & Public Health Agencies

15. Cold-chain Pharma Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Cold-chain Pharma Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Cold-chain Pharma Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Cold-chain Pharma Market

19. China Cold-chain Pharma Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Americold Realty Trust, Inc.
  • 20.6. AmerisourceBergen Corporation
  • 20.7. BioCold Technologies S.A.S
  • 20.8. C.H. Robinson Worldwide, Inc.
  • 20.9. Catalent, Inc.
  • 20.10. Clinigen Group PLC
  • 20.11. Conestoga Cold Storage Ltd.
  • 20.12. Continental AG
  • 20.13. CWT Ltd.
  • 20.14. DB Schenker
  • 20.15. DHL International GmbH
  • 20.16. DSV A/S
  • 20.17. Emergent Cold LatAm Management LLC
  • 20.18. FedEx Corporation
  • 20.19. FreezPak Logistics
  • 20.20. HCL Technologies Limited
  • 20.21. Helapet ltd.
  • 20.22. Interstate Cold Storage, Inc.
  • 20.23. JWD InfoLogistics Public Co. Ltd.
  • 20.24. Keppel Telecommunications & Transportation Ltd,
  • 20.25. Kerry Logistics Network Limited by SF Holding Co., Ltd.
  • 20.26. Kuehne + Nagel Management AG
  • 20.27. Lineage, Inc.
  • 20.28. Maersk A/S
  • 20.29. NewCold Cooperatief UA
  • 20.30. OOCL Logistics Limited by COSCO SHIPPING Holdings Co. Limited
  • 20.31. SCG Logistics Management Co Ltd.
  • 20.32. Tiong Nam Logistics Holdings Berhad
  • 20.33. United Parcel Service, Inc.
  • 20.34. Ych Group
  • 20.35. Yusen Logistics Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLD-CHAIN PHARMA MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLD-CHAIN PHARMA MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PLASMA-DERIVED THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RECOMBINANT PROTEINS & ENZYMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COAGULATION FACTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY IMMUNOGLOBULINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ALLOGENEIC CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUTOLOGOUS CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARIES & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INVESTIGATIONAL MEDICINAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY GLP-1 & OTHER PEPTIDE HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FERTILITY & REPRODUCTIVE MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ROUTINE IMMUNIZATION VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRAVEL & SPECIALTY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ACTIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PASSIVE PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYO PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DRY SHIPPER TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LN2 VAPOR STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULTRA-LOW (-60 TO -86 °C), 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COLD ROOMS & WAREHOUSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC FREEZERS & LN2 TANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FREEZERS (-20 °C CLASS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMACEUTICAL REFRIGERATORS (2-8 °C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ULT FREEZERS (-80 °C CLASS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORT EQUIPMENT, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AIR CARGO CONTAINERS (ULDS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE PORTABLE COOLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY OCEAN REEFER CONTAINERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REEFER TRUCKS & VANS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL LOGISTICS, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY ANCILLARY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SITE SUPPLY AND RETURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMPLIANCE & QUALITY, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY AUDITS & GDP TRAINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LANE VALIDATION & RISK ASSESSMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY QUALIFICATION (IQ/OQ/PQ), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY STORAGE & WAREHOUSING, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LONG-TERM GMP STORAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY TRANSPORTATION, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY FIRST-MILE PICKUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LAST-MILE DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LINE-HAUL TRANSPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REVERSE LOGISTICS & RETURNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY COMMERCIAL DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY DIRECT-TO-PATIENT/HOME DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HUMANITARIAN & NGO SUPPLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACY FULFILLMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 254. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 255. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 256. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CAMPAIGNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 259. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD BANKS & PLASMA CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL SITES & DEPOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 265. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 266. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CMOS & CDMOS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 268. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 269. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 270. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 271. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 273. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 274. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 275. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY PHARMA & BIOTECH MANUFACTURERS, 2018-2032 (USD MILLION)
  • TABLE 277. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY EMERGING BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY LARGE PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 283. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 284. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY RETAIL & SPECIALTY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 287. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY VACCINATION CENTERS & PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. GLOBAL COLD-CHAIN PHARMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 290. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 291. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 293. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY BLOOD & PLASMA PRODUCTS, 2018-2032 (USD MILLION)
  • TABLE 294. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CELL & GENE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 295. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CLINICAL TRIAL MATERIALS, 2018-2032 (USD MILLION)
  • TABLE 296. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY INSULINS & HORMONES, 2018-2032 (USD MILLION)
  • TABLE 297. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY SPECIALTY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 298. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 299. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PANDEMIC & EMERGING VACCINES, 2018-2032 (USD MILLION)
  • TABLE 300. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY TEMPERATURE RANGE, 2018-2032 (USD MILLION)
  • TABLE 302. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY CRYOGENIC (<= -150 °C), 2018-2032 (USD MILLION)
  • TABLE 303. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY FROZEN (-20 TO -40 °C), 2018-2032 (USD MILLION)
  • TABLE 304. AMERICAS COLD-CHAIN PHARMA MARKET SIZE, BY REFRIGERATED (2-8 °C), 2018-2032 (USD MILLION)

TABLE 305.